Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ImageneBio, Inc.

Capitalization 66.1M 57.78M 52.2M 49.94M 90.83M 6.11B 94.42M 624M 247M 2.92B 248M 243M 10.55B P/E ratio 2026 *
-1.98x
P/E ratio 2027 * -2.43x
Enterprise value 66.1M 57.78M 52.2M 49.94M 90.83M 6.11B 94.42M 624M 247M 2.92B 248M 243M 10.55B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.50%
1 week+1.20%
Current month-12.05%
1 month-14.47%
3 months-9.08%
6 months-35.34%
Current year-14.35%
1 week 5.82
Extreme 5.8221
6.5
1 month 5.82
Extreme 5.8221
7.25
Current year 5.82
Extreme 5.8221
7.6
1 year 5.7
Extreme 5.7
18
3 years 5.7
Extreme 5.7
18
5 years 5.7
Extreme 5.7
18
10 years 5.7
Extreme 5.7
18
Change 5d. change 1-year change 3-years change Capi.($)
-1.50%+1.20% - - 66.08M
-0.72%-4.60%-11.02%-8.56% 42.78B
-0.44%-5.67%+11.58%+27.82% 31.5B
-0.24%-3.29%+15.77%+44.41% 29.99B
+1.10%-5.60%-9.21%-16.86% 27.65B
-0.22%-3.60%+143.04%+320.11% 18.8B
-1.32%-6.10%+48.37%+109.92% 13.87B
+1.48%-4.29%+41.67%+158.40% 12.78B
-0.29%-4.80%+21.98%-2.54% 12.39B
-1.59%-3.85%+116.38%+112.00% 11.76B
Average -0.37%-3.66%+42.06%+82.74% 20.16B
Weighted average by Cap. -0.23%-4.07%+28.01%+60.68%

Financials

2026 *2027 *
Net sales - -
Net income -44.86M -39.22M -35.43M -33.89M -61.65M -4.15B -64.08M -423M -168M -1.98B -168M -165M -7.16B -61.49M -53.75M -48.56M -46.46M -84.49M -5.69B -87.83M -580M -230M -2.72B -231M -226M -9.81B
Net Debt - -
Logo ImageneBio, Inc.
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
Employees
-
Date Price Change Volume
13/03/26 5.910 $ -1.50% 60,725
12/03/26 6.000 $ -0.17% 67,463
11/03/26 6.010 $ -0.99% 42,871
10/03/26 6.070 $ +2.53% 50,416
09/03/26 5.920 $ +1.37% 18,894
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.910USD
Average target price
16.00USD
Spread / Average Target
+170.73%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW